Company intelligence / Profile preview

Xinglian Pharmaceutical

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Xinglian Pharmaceutical is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of next-generation targeted radiopharmaceuticals. The company utilizes its proprietary Radionuclide Drug Conjugate (RDC) platform to create precision diagnostic and therapeutic agents for various oncology indications. Its lead programs focus on high-value targets such as PSMA and FAP, employing isotopes like Lutetium-177 and Actinium-225. Backed by top-tier investors including Sequoia China and GL Ventures, Xinglian is positioned as a key player in the emerging field of nuclear medicine in Asia.

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalPeptideBiologic
Industry: Biotech

Partnerships

ITM (Isotope Technologies Munich)

Beyond the preview

Go deeper on Xinglian Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xinglian Pharmaceutical.

Explore the full profile